国产精品ⅴ无码大片在线看,激情影院内射美女,动物与人性生活一区二区三区性生活激情视频,久久久久免费毛a片免费一瓶梅

    • 尊龍凱時·(中國區)人生就是搏!

    EN
    ×
    EN

    • 業務咨詢

      中國：

      Email: marketing@www.msjidi.com

      業務咨詢專線：400-780-8018

      （僅限服務咨詢，其他事宜請撥打川沙總部電話）

      川沙總部電話: +86 (21) 5859-1500

      海外：

      +1(781)535-1428(U.S.)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com
    在線留言×

    搜索結果包含 Compound 的內容

    Jul 10,2025
    TBN是一種治療缺血性卒中的新型臨床候選藥物，本研究中TBN通過尊龍凱時合成
    TBN (purity 99.3%) used in this study was synthesized by Medicilon.
    查看更多
    Jul 10,2025
    跨膜結構域寡聚體的結構測定新方法，其中TriNTA通過尊龍凱時合成
    TriNTA was synthesized by Medicilon.
    查看更多
    Jul 03,2025
    特異性RET抑制劑CPT可改善阿爾茨海默病，本研究中CPT由尊龍凱時化學部門合成
    The compound was synthesized for Cerepeut Inc. by the Chemistry Branch of Medicilon.
    查看更多
    Jul 02,2025
    口服有效的ADAMTS-4/5抑制劑異吲哚啉酰胺衍生物，可治療骨關節炎，本研究中部分化合物通過尊龍凱時合成
    Part of the compound synthesis was performed at Medicilon.
    查看更多
    Jul 06,2023
    設計合成一系列用于治療胃癌的多靶點受體酪氨酸激酶抑制劑，并進行生物學評價。其中藥代動力學分析通過尊龍凱時進行
    Gastric cancer is the second most lethal cancer across the world. Compounds 8f, inhibits FGFR1 signaling pathways as well as induces cell apoptosis, is a potential agent for the treatment of gastric c
    查看更多
    Jul 06,2023
    FBPase是與腫瘤和2型糖尿病相關的一個有前景的靶點。化合物W8對FBPase表現出高選擇性。W8的藥代動力學研究通過尊龍凱時進行
    Fructose-1,6-bisphosphatase (FBPase) is a promising target associated with cancer and type 2 diabetes. Compounds W8 and W8k exhibit high selectivity against FBPase and W8 effectively reduces blood glu
    查看更多
    Jul 06,2023
    藥物發現中的挑戰之一是識別高質量的先導化合物。此研究中PK結果表明L12可作為針對PDE5的先導化合物，進一步研究和開發。L12的PK分析通過尊龍凱時進行
    Scaffold hopping refers to computer-aided screening for active compounds with different structures against the same receptor to enrich privileged scaffolds, which is a topic of high interest in organi
    查看更多
    Jul 06,2023
    XY153是一種有潛力的先導化合物，可用于開發針對急性髓系白血病。XY153在體外具有良好的代謝穩定性。所有肝微粒體測定均通過尊龍凱時進行
    Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The representative Compound 8l (XY153), a novel BD2-select
    查看更多
    Jul 06,2023
    基于構效關系分析，合成了一種結構簡化但具有優異防污活性的化合物。優化后的化合物通過尊龍凱時合成
    Biofouling poses one of the most serious problems to marine industry and aquaculture development. Five structurally similar compounds were isolated from the crude extract of a marine Streptomyces stra
    查看更多
    Jul 06,2023
    PDE1是與中樞和外周疾病密切相關的藥物靶點，研究人員合成一種PDE1 抑制劑在大鼠肝微粒體中具有良好的代謝穩定性。其中穩定性測試通過尊龍凱時進行
    Phosphodiesterase-1 (PDE1) is a promising drug target closely related to central and peripheral diseases. Compound 2j with the IC50 of 21 nM against PDE1B, shows good metabolic stability in the rat li
    查看更多
    Jun 28,2023
    開發并驗證新的LC-MS/MS方法，用于定量人血漿中達拉非尼及其主要代謝物羥基達拉非尼 (OHD)。本研究中OHD(純度>99%)通過尊龍凱時合成
    OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
    查看更多
    99%)通過尊龍凱時合成">
    Jun 28,2023
    SKLB-197是一種有效且高度選擇性的ATR抑制劑，PK研究通過尊龍凱時進行
    SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
    查看更多
    Jun 28,2023
    研究用于肺癌和黑色素瘤細胞肺轉移的選擇性PAK4抑制劑的合成，此選擇性PAK4抑制劑的PK研究通過尊龍凱時進行
    The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic
    查看更多
    May 29,2023
    美研 | Beautiful Chemistry Issue 4 : Direct Cyclopropanation by Organoelectrocatalysis
    In summary, the efficient and scalable intramolecular cyclopropanation of active methylene compounds via electrocatalysis with an organic catalyst can solve challenges from the transition metal catalyzed alkene cyclopropanation of functionalized compound
    查看更多

    川沙總部

    地址: 上海市浦東新區川大路585號

    郵編: 201299

    電話: +86 (21) 5859-1500（總機）

    傳真: +86 (21) 5859-6369

    業務咨詢

    中國：

    Email: marketing@medicilon.com

    業務咨詢專線：400-780-8018

    （僅限服務咨詢，其他事宜請撥打川沙
    總部電話）

     

    海外：

    Email:?marketing@medicilon.com

    Tel: +1 (617) 888-9294(U.S.)

    Tel: 0044 7790 816 954 (Europe)

    Tel: +82 70-8269-5849 (Korea)

    Tel: +81 80-4421-6898 (Japan)

    ? 2022 上海尊龍凱時生物醫藥股份有限公司 保留所有權利 滬ICP備10216606號-3
    滬公網安備 31011502012909號|網站地圖|技術支持：集錦科技
    安全性評價 溶瘤病毒 PDX模型 IND申報 AAALAC
    ×
    搜索驗證